Unum Therapeutics: IND Application Active For ACTR087 With SEA-BCMA

Unum Therapeutics Inc., a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, said that an investigational new drug or IND application is now active for ACTR087 T cells in combination with a novel antibody, SEA-BCMA, for the treatment of adult patients with relapsed/refractory multiple myeloma.

from RTT - Biotech http://ift.tt/2w2C70h
via IFTTT